BRPI0409984A - process for changing insulin pharmacokinetics - Google Patents

process for changing insulin pharmacokinetics

Info

Publication number
BRPI0409984A
BRPI0409984A BRPI0409984-2A BRPI0409984A BRPI0409984A BR PI0409984 A BRPI0409984 A BR PI0409984A BR PI0409984 A BRPI0409984 A BR PI0409984A BR PI0409984 A BRPI0409984 A BR PI0409984A
Authority
BR
Brazil
Prior art keywords
insulin
processes
present
prevention
treatment
Prior art date
Application number
BRPI0409984-2A
Other languages
Portuguese (pt)
Inventor
Ronald J Pettis
Noel Harvey
Barry Ginsberg
Original Assignee
Becton Dickinson Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/429,973 external-priority patent/US7722595B2/en
Priority claimed from US10/704,035 external-priority patent/US20050010193A1/en
Application filed by Becton Dickinson Co filed Critical Becton Dickinson Co
Publication of BRPI0409984A publication Critical patent/BRPI0409984A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/46—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for controlling depth of insertion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3286—Needle tip design, e.g. for improved penetration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)

Abstract

"PROCESSO PARA ALTERAR A FARMACOCINéTICA DA INSULINA". A presente invenção se refere a processos para a administração de insulina a um compartimento intradérmico da pelo de um indivíduo, de preferência à vascularização dérmica do compartimento intradérmico. Os processos da presente invenção aumentam os parâmetros farmacocinéticos e farmacodinâmicos da insulina distribuída e resultam eficazmente em uma eficácia clínica superior no tratamento e/ou prevenção de diabetes melito. Os processos da presente invenção proporcionam um melhor controle glicêmico tanto dos níveis de glicose sangüínea não em jejum (isto é, pós-prandiais), quanto em jejum e, portanto, têm uma maior eficácia terapêutica no tratamento, prevenção e/ou controle de diabetes, com relação a processos tradicionais de distribuição de insulina, incluindo a distribuição subcutânea de insulina."Process for changing insulin pharmacokinetics". The present invention relates to methods for administering insulin to an intradermal compartment of an individual's hair, preferably to dermal vascularization of the intradermal compartment. The processes of the present invention increase the pharmacokinetic and pharmacodynamic parameters of distributed insulin and effectively result in superior clinical efficacy in the treatment and / or prevention of diabetes mellitus. The processes of the present invention provide improved glycemic control of both fasting (i.e. postprandial) and fasting blood glucose levels and thus have greater therapeutic efficacy in the treatment, prevention and / or control of diabetes. , with respect to traditional insulin delivery processes, including subcutaneous insulin distribution.

BRPI0409984-2A 2003-05-06 2004-05-06 process for changing insulin pharmacokinetics BRPI0409984A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/429,973 US7722595B2 (en) 2002-05-06 2003-05-06 Method and device for controlling drug pharmacokinetics
US50095603P 2003-09-05 2003-09-05
US10/704,035 US20050010193A1 (en) 2002-05-06 2003-11-06 Novel methods for administration of drugs and devices useful thereof
US52383103P 2003-11-19 2003-11-19
PCT/US2004/014033 WO2004101023A2 (en) 2003-05-06 2004-05-06 A method for altering insulin pharmacokinetics

Publications (1)

Publication Number Publication Date
BRPI0409984A true BRPI0409984A (en) 2006-05-09

Family

ID=33459121

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409984-2A BRPI0409984A (en) 2003-05-06 2004-05-06 process for changing insulin pharmacokinetics

Country Status (8)

Country Link
EP (1) EP1620145A4 (en)
JP (1) JP2007517768A (en)
KR (1) KR20060009303A (en)
AU (1) AU2004238257A1 (en)
BR (1) BRPI0409984A (en)
CA (1) CA2524444A1 (en)
MX (1) MXPA05011768A (en)
WO (1) WO2004101023A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
US10105317B2 (en) * 2009-07-07 2018-10-23 Anpac Bio-Medical Science Co., Ltd. Method of drug delivery
EP3134110A1 (en) * 2014-04-25 2017-03-01 Sanofi New administration routes of insulin, insulin analogs or derivatives of insulin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6623457B1 (en) * 1999-09-22 2003-09-23 Becton, Dickinson And Company Method and apparatus for the transdermal administration of a substance
US20020156453A1 (en) * 1999-10-14 2002-10-24 Pettis Ronald J. Method and device for reducing therapeutic dosage
US6565532B1 (en) * 2000-07-12 2003-05-20 The Procter & Gamble Company Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup
US6607513B1 (en) * 2000-06-08 2003-08-19 Becton, Dickinson And Company Device for withdrawing or administering a substance and method of manufacturing a device
EP1381415A1 (en) * 2001-04-13 2004-01-21 Becton, Dickinson and Company Method of intradermally injecting substances
CN1253220C (en) * 2001-06-29 2006-04-26 贝克顿迪肯森公司 Intradermal delivery of vaccines and gene therapies via microtubules
WO2003022330A2 (en) * 2001-09-12 2003-03-20 Becton, Dickinson And Company Microneedle-based pen device for drug delivery and method for using same

Also Published As

Publication number Publication date
MXPA05011768A (en) 2006-01-26
CA2524444A1 (en) 2004-11-25
EP1620145A2 (en) 2006-02-01
WO2004101023A2 (en) 2004-11-25
KR20060009303A (en) 2006-01-31
WO2004101023A3 (en) 2007-03-01
EP1620145A4 (en) 2010-08-25
JP2007517768A (en) 2007-07-05
AU2004238257A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
Bode et al. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes
Hollander et al. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes
Kann et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride
Raskin et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs
Garg et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine
Raskin et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes.
McSorley et al. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus
Bode Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues—aspart, lispro, and glulisine
Pitt et al. Factors influencing insulin absorption around exercise in type 1 diabetes
ES2334258T3 (en) CONTROL OF BLOOD GLUCOSE IN THE TREATMENT OF DIABETES USED BY PULMONALLY ADMINISTERED INSULIN IN COMBINATION WITH BASAL INSULIN.
Black et al. The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation
Maiorino et al. Treatment satisfaction and glycemic control in young type 1 diabetic patients in transition from pediatric health care: CSII versus MDI
NZ592283A (en) Combination of an insulin and the GLP-1 agonist AVE0010
Woo A review of the clinical efficacy and safety of insulin degludec and glargine 300 U/mL in the treatment of diabetes mellitus
Quaba et al. A users guide for reducing the pain of local anaesthetic administration
Davidson et al. Biphasic insulin aspart 30: literature review of adverse events associated with treatment
BRPI0409984A (en) process for changing insulin pharmacokinetics
Ristic et al. Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus
Standl Insulin analogues–State of the art
Joshi et al. Designer insulins regimens in clinical practice-pilot multicenter indian study
Choe et al. New therapeutic options for treating type-2 diabetes: a review of insulin analogs and premixed insulin analogs
Kapural et al. Decreased insulin requirements with spinal cord stimulation in a patient with diabetes
Cander et al. The effect of basal analog insulin on the glycemic variability in type 2 diabetics.
Cypryk et al. New faster-acting insulin Fiasp®—do we need a new meal-time insulin?
Faradji et al. Use of Insulin in Outpatient Diabetes Management

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal: dismissal of application maintained